Pulmonary alveolar proteinosis: time to shift?

Area of Science:

• Pulmonary Medicine
• Immunology
• Genetics

Background:

• Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by surfactant accumulation in alveoli.
• It is classified into hereditary, secondary, and autoimmune (aPAP) forms, all linked to impaired alveolar macrophage catabolism of surfactant.
• This accumulation impairs gas exchange and increases infection risk due to compromised myeloid cell immunity.

Purpose of the Study:

• To review the pathogenesis, classification, and current treatment strategies for Pulmonary alveolar proteinosis (PAP).
• To highlight recent therapeutic advances in autoimmune PAP (aPAP).

Main Methods:

• Literature review of PAP pathogenesis, classification, and treatment modalities.
• Analysis of genetic mutations in hereditary PAP (e.g., GM-CSF signaling pathway, GATA2).
• Review of etiological factors for secondary PAP and the role of GM-CSF autoantibodies in aPAP.

Main Results:

• PAP pathogenesis commonly involves defective surfactant metabolism by alveolar macrophages.
• Hereditary PAP links to GM-CSF signaling mutations, while aPAP is associated with GM-CSF autoantibodies.
• Secondary PAP arises from diverse conditions including malignancies, environmental exposures, and autoimmune disorders.

Conclusions:

• PAP treatment is etiology-dependent.
• Emerging therapies for aPAP may involve inhaled GM-CSF, offering an alternative to whole lung lavage.
• Understanding PAP subtypes is crucial for effective management and improved patient outcomes.